Abstract
Objective:
Stilboestrol phosphate (ST 52) was evaluated on pain, general status, life expectancy and PSA, in a retrospective study of patients with prostatic carcinoma and relapse to hormonal treatment.
Material and methods:
32 patients were treated by infusion of Stilboestrol phosphate at a daily escalating dose from 1.2 to 3 g over a period of 10 days, then subsequently oral administration.
Results:
Minor complications, especially nausea were observed in 12 cases but no major complication or interruption of treatment. Improvement for pain alone or with general status was obtained in 50% (16 cases) at 3 months, but at one year only 10% were still improved. Median survival was 8 months, with 19.4 months for responders at the end of infusions and 4.2 months for non-responders-respectively.
Conclusion:
Stilboestrol phosphate can obtain a clinical response with low morbidity when relapse to hormonal treatment occurs. Infusion responders have a better life expectancy.
Publication types
-
Clinical Trial
-
English Abstract
MeSH terms
-
Administration, Oral
-
Antineoplastic Agents, Hormonal / administration & dosage
-
Antineoplastic Agents, Hormonal / adverse effects
-
Antineoplastic Agents, Hormonal / therapeutic use*
-
Carcinoma / drug therapy*
-
Diethylstilbestrol / administration & dosage
-
Diethylstilbestrol / adverse effects
-
Diethylstilbestrol / therapeutic use*
-
Drug Resistance, Neoplasm*
-
Estrogens, Non-Steroidal / administration & dosage
-
Estrogens, Non-Steroidal / adverse effects
-
Estrogens, Non-Steroidal / therapeutic use*
-
Follow-Up Studies
-
Health Status
-
Humans
-
Infusions, Intravenous
-
Life Expectancy
-
Male
-
Middle Aged
-
Nausea / chemically induced
-
Neoplasm Recurrence, Local / drug therapy
-
Pain / prevention & control
-
Prostate-Specific Antigen / analysis
-
Prostatic Neoplasms / drug therapy*
-
Remission Induction
-
Retrospective Studies
-
Survival Rate
Substances
-
Antineoplastic Agents, Hormonal
-
Estrogens, Non-Steroidal
-
Diethylstilbestrol
-
Prostate-Specific Antigen